Headlines about Dipexium Pharmaceuticals (NASDAQ:DPRX) have trended somewhat positive on Wednesday, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dipexium Pharmaceuticals earned a media sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also assigned media stories about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.
Separately, Zacks Investment Research lowered Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 3rd.
Dipexium Pharmaceuticals (NASDAQ:DPRX) remained flat at $1.30 on Wednesday. The company had a trading volume of 9,792 shares. Dipexium Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $17.75. The company’s 50 day moving average is $1.28 and its 200 day moving average is $3.35. The firm’s market cap is $14.45 million.
Dipexium Pharmaceuticals, Inc is a biopharmaceutical company. The Company was focused on the development and commercialization of Locilex (pexiganan cream 0.8%). The Company intends to develop and commercialize Locilex either directly or through one or more partnerships. The Company’s subsidiary is Dipexium Pharmaceuticals Ireland, Limited.
